share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Sanders Reginald J.

SEC ·  Jan 8 15:15

Summary by Moomoo AI

EyePoint Pharmaceuticals, Inc. has reported a transaction involving Sanders Reginald J. on January 8, 2025. The specific details of the transaction, including the type, quantity, and price of securities involved, are not provided in the available information.The reporting person's address is listed as C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472. The relationship between Sanders Reginald J. and the issuer is not specified in the given announcement. Further information about the nature of the transaction and its potential impact on the company's stock ownership structure is not available at this time.
EyePoint Pharmaceuticals, Inc. has reported a transaction involving Sanders Reginald J. on January 8, 2025. The specific details of the transaction, including the type, quantity, and price of securities involved, are not provided in the available information.The reporting person's address is listed as C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472. The relationship between Sanders Reginald J. and the issuer is not specified in the given announcement. Further information about the nature of the transaction and its potential impact on the company's stock ownership structure is not available at this time.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated